Maria Røed Skårderud1, Anne Polk2, Kirsten Kjeldgaard Vistisen3, Finn Ole Larsen4, Dorte Lisbet Nielsen5. 1. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK- 2730 Herlev, Denmark. Electronic address: mariaskarderud@gmail.com. 2. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK- 2730 Herlev, Denmark. Electronic address: anne.polk@hotmail.com. 3. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK- 2730 Herlev, Denmark. Electronic address: kirsten.vistisen@regionh.dk. 4. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK- 2730 Herlev, Denmark. Electronic address: finn.ole.larsen@regionh.dk. 5. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK- 2730 Herlev, Denmark. Electronic address: dorte.nielsen.01@regionh.dk.
Abstract
PURPOSE: Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib. METHOD: We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference abstracts, for studies in English including ≥30 patients, evaluating the efficacy and safety of regorafenib in patients with metastatic colorectal cancer. A meta-analysis was conducted on the published, randomized phase III trials. RESULTS: 24 eligible studies were included. In two phase III trials, regorafenib significantly increased overall survival (OS), progression free survival (PFS), and disease control rate when compared to placebo. Survival benefits of 1.4 and 2.5 months were presented. The meta-analysis indicated a significant greater treatment effect on OS (hazard ratio 0.67) and PFS (hazard ratio 0.40), compared to placebo. The non-randomized studies mostly supported these results. The most frequently reported adverse events were hand-foot-skin reaction (25%-86%), hypertension (11%-47%) and fatigue (2%-73%). CONCLUSION: Large phase III randomized trials indicate that regorafenib provides a benefit in OS and PFS when compared to placebo. Adverse events were common, but manageable and typical of multi-target tyrosine kinase inhibitors. Further research is needed to investigate alternative approaches to the dosing of regorafenib and to explore clinical and molecular biomarkers that can guide patient selection.
PURPOSE: Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib. METHOD: We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference abstracts, for studies in English including ≥30 patients, evaluating the efficacy and safety of regorafenib in patients with metastatic colorectal cancer. A meta-analysis was conducted on the published, randomized phase III trials. RESULTS: 24 eligible studies were included. In two phase III trials, regorafenib significantly increased overall survival (OS), progression free survival (PFS), and disease control rate when compared to placebo. Survival benefits of 1.4 and 2.5 months were presented. The meta-analysis indicated a significant greater treatment effect on OS (hazard ratio 0.67) and PFS (hazard ratio 0.40), compared to placebo. The non-randomized studies mostly supported these results. The most frequently reported adverse events were hand-foot-skin reaction (25%-86%), hypertension (11%-47%) and fatigue (2%-73%). CONCLUSION: Large phase III randomized trials indicate that regorafenib provides a benefit in OS and PFS when compared to placebo. Adverse events were common, but manageable and typical of multi-target tyrosine kinase inhibitors. Further research is needed to investigate alternative approaches to the dosing of regorafenib and to explore clinical and molecular biomarkers that can guide patient selection.
Authors: Laurence Booth; Jane L Roberts; Rumeesa Rais; Richard E Cutler; Irmina Diala; Alshad S Lalani; John F Hancock; Andrew Poklepovic; Paul Dent Journal: J Cell Physiol Date: 2018-09-10 Impact factor: 6.384
Authors: Erdem Bangi; Celina Ang; Peter Smibert; Andrew V Uzilov; Alexander G Teague; Yevgeniy Antipin; Rong Chen; Chana Hecht; Nelson Gruszczynski; Wesley J Yon; Denis Malyshev; Denise Laspina; Isaiah Selkridge; Hope Rainey; Aye S Moe; Chun Yee Lau; Patricia Taik; Eric Wilck; Aarti Bhardwaj; Max Sung; Sara Kim; Kendra Yum; Robert Sebra; Michael Donovan; Krzysztof Misiukiewicz; Eric E Schadt; Marshall R Posner; Ross L Cagan Journal: Sci Adv Date: 2019-05-22 Impact factor: 14.136
Authors: Wagdy M Eldehna; Ghada S Hassan; Sara T Al-Rashood; Tarfah Al-Warhi; Ahmed E Altyar; Hamad M Alkahtani; Abdulrahman A Almehizia; Hatem A Abdel-Aziz Journal: J Enzyme Inhib Med Chem Date: 2019-12 Impact factor: 5.051
Authors: Flavia Fondevila; Carolina Méndez-Blanco; Paula Fernández-Palanca; Javier González-Gallego; José L Mauriz Journal: Exp Mol Med Date: 2019-09-24 Impact factor: 8.718